Latest

donanemab

·September 25, 2024·3 min read

Alzheimer’s Drug Faces Scrutiny Over Safety, Efficacy Concerns

The FDA-approved Alzheimer’s drug donanemab is under scrutiny due to concerns about its effectiveness and safety, according to an investigation. The study highlights multiple patient deaths during trials, design flaws, and the financial ties of panelists who recommended the drug's approval.

Featured Neurology Neuroscience

·June 10, 2024·2 min read

FDA Panel Backs Donanemab: New Hope for Early Alzheimer’s Treatment

Eli Lilly’s Alzheimer’s drug, Donanemab, has been recommended for FDA approval by an independent panel. The drug has shown promise in slowing early-stage Alzheimer’s, despite risks like brain swelling. This recommendation follows a prior FDA rejection due to insufficient data. If approved, Donanemab could revolutionize Alzheimer's treatment, offering new hope for patients and their families.

Featured Neurology Neuroscience

·July 17, 2023·5 min read

Donanemab: A Promising Step Forward in Early-Stage Alzheimer’s Treatment

A third new Alzheimer's drug, donanemab, is set for FDA approval, marking a significant step in slowing the progression of the disease. However, these treatments, which work best in the disease's early stages, may not suffice for patients with advanced Alzheimer's.

Featured Neurology Neuroscience

·May 3, 2023·3 min read

Alzheimer’s Drug Donanemab Slows Cognitive and Functional Decline in Phase 3 Study

Findings from a Phase 3 study show donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Donanemab met the primary endpoint of change, which measured measures cognition and activities of daily living such as managing finances, driving, engaging in hobbies, and conversing about current events, from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale (iADRS). All secondary endpoints of cognitive and functional decline were also met and showed highly statistically significant clinical benefits with similar magnitude. Results suggest that people in the early pathological stage of Alzheimer's could be the most responsive to therapeutics targeting amyloid.